2023
Cross-Species Convergence of Brain Transcriptomic and Epigenomic Findings in Posttraumatic Stress Disorder: A Systematic Review
Núñez-Rios D, Martínez-Magaña J, Nagamatsu S, Krystal J, Martínez-González K, Giusti-Rodríguez P, Montalvo-Ortiz J. Cross-Species Convergence of Brain Transcriptomic and Epigenomic Findings in Posttraumatic Stress Disorder: A Systematic Review. Complex Psychiatry 2023, 9: 100-118. PMID: 37404872, PMCID: PMC10315001, DOI: 10.1159/000529536.Peer-Reviewed Original ResearchG protein-coupled receptorsPosttraumatic stress disorderEpigenomic findingsEpigenomic studiesEpigenomic profilesTranscriptomic modificationsEpigenetic studiesBrain transcriptomicsBiological pathwaysComplex multifactorial disorderGenesBrain tissueGene-environment interplayStress disorderSpeciesHuman postmortem samplesChemical synaptic transmissionSystematic literature searchEnvironmental factorsCurrent knowledge gapsPotential roleOrexin pathwayPathwayBrain alterationsPeripheral tissues
2019
In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation
Davis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Carson RE, Krystal JH, Esterlis I. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 11490-11495. PMID: 31085640, PMCID: PMC6561298, DOI: 10.1073/pnas.1818871116.Peer-Reviewed Original ResearchConceptsMGluR5 availabilitySuicidal ideationHC individualsPathophysiology of PTSDLimbic brain regionsVolume of distributionHealthy comparison controlsSuicide risk managementPositron emission tomographyReceptor 5Venous input functionsBrain regionsPTSD individualsEmission tomographyMDD individualsVivo evidenceRecent evidencePotential roleMGluR5PTSDComparison controlsDysregulationMDDIdeationIndividuals
2006
MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases
Mason GF, Krystal JH. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR In Biomedicine 2006, 19: 690-701. PMID: 16986118, DOI: 10.1002/nbm.1080.Peer-Reviewed Original ResearchConceptsPsychiatric diseasesMagnetic resonance spectroscopyGlial abnormalitiesPsychiatric disordersBiochemical markersNon-invasive techniqueNeuropsychiatric disordersPotential roleDrug developmentDrug discoveryMRS techniquesDiseaseDisordersStudy of mechanismsTreatmentLines of investigationAbnormalitiesNeurochemistryDrug delivery
2000
Antidepressant effects of ketamine in depressed patients
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D, Krystal J. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47: 351-354. PMID: 10686270, DOI: 10.1016/s0006-3223(99)00230-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepressive Disorder, MajorDose-Response Relationship, DrugDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamic AcidHumansInjections, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSeverity of Illness IndexConceptsMajor depressionN-methyl-D-aspartate receptor antagonistBrain glutamate systemDouble-blind trialDouble-blind conditionsTreatment of depressionMechanism of actionPlacebo infusionAntidepressant effectsIntravenous treatmentSingle doseReceptor antagonistDepressed patientsGlutamate systemDepressive symptomsPreclinical researchKetamine hydrochlorideDepressionPotential roleTest dayTreatment effectsPatientsKetamineSaline solutionTreatment